Dr. Mark S. Dacey, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 361
Licensed in Colorado since 2010, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Michigan Medical School
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
CO license 49002 (first issued 2010; active) -
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician
CO license 49002 (first issued 2010; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uch-Memorial Health System Colorado Springs, CO
- Cheyenne Regional Medical Center Cheyenne, WY
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 361
- Services billed
- 4,091
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient complete exam of visual system | 913 | 254 |
| Imaging of retina | 875 | 238 |
| Established patient office or other outpatient visit, 30-39 minutes | 197 | 90 |
| Photography of the retina | 151 | 86 |
| Injection, aflibercept, 1 mg | 144 | 18 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 94 | 67 |
| Injection of drug into eye | 84 | 28 |
| Established patient problem focused exam of visual system | 71 | 48 |
| New patient office or other outpatient visit, 45-59 minutes | 36 | 36 |
| Removal of eyelashes using forceps | 25 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Denver, CO | 260 |
| Methotrexate (methotrexate sodium) Other prescribers in Denver, CO | 222 |
| Difluprednate | 188 |
| Timolol Maleate Other prescribers in Denver, CO | 129 |
| Mycophenolate Mofetil Other prescribers in Denver, CO | 113 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Denver, CO | 110 |
| Latanoprost Other prescribers in Denver, CO | 104 |
| Brimonidine Tartrate Other prescribers in Denver, CO | 90 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Denver, CO | 90 |
| Prednisone Other prescribers in Denver, CO | 81 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 37 payments worth $26,071 in total to this clinician.
| AbbVie Inc. | $11,702 |
|---|---|
| Genentech USA, Inc. | $7,177 |
| Ani Pharmaceuticals, Inc. | $3,612 |
| Bausch & Lomb Americas Inc. | $3,580 |
| Compensation for services other than consulting (speaking, faculty) | $10,875 |
|---|---|
| Consulting Fee | $9,100 |
| Honoraria | $3,425 |
| Travel and Lodging | $1,460 |
| Food and Beverage | $712 |
| Speaking at a medical education program | $500 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Nov 15, 2025 | Consulting Fee | $6,100 |
| AbbVie Inc. Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) OZURDEX · EYE CARE | $5,250 |
| AbbVie Inc. Dec 22, 2025 | Compensation for services other than consulting (speaking, faculty) OZURDEX · EYE CARE | $2,250 |
| AbbVie Inc. Dec 22, 2025 | Compensation for services other than consulting (speaking, faculty) OZURDEX · EYE CARE | $2,250 |
| Bausch & Lomb Americas Inc. Sep 2, 2025 | Consulting Fee XIPERE · Ophthalmology | $2,000 |
| Ani Pharmaceuticals, Inc. Sep 17, 2025 | Honoraria PURIFIED CORTROPHIN GEL · Treatment of certain chronic autoimmune disorders including acute exacerbations | $1,850 |
| Ani Pharmaceuticals, Inc. Nov 20, 2025 | Honoraria YUTIQ · Treatment of chronic non-infectious uveitis affecting the posterior segment of t | $1,575 |
| AbbVie Inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) OZURDEX · EYE CARE | $1,125 |
| Bausch & Lomb Americas Inc. Sep 2, 2025 | Consulting Fee XIPERE · Ophthalmology | $1,000 |
| Bausch & Lomb Americas Inc. Jul 17, 2025 | Speaking at a medical education program XIPERE · Ophthalmology | $500 |
All 18 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 22, 2025 | Compensation for services other than consulting (speaking, faculty) OZURDEX · EYE CARE | $2,250 |
| AbbVie Inc. Dec 22, 2025 | Compensation for services other than consulting (speaking, faculty) OZURDEX · EYE CARE | $2,250 |
| AbbVie Inc. Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) OZURDEX · EYE CARE | $5,250 |
| AbbVie Inc. Dec 15, 2025 | Travel and Lodging OZURDEX · EYE CARE · travel to SAN ANTONIO, TX · in-kind | $387 |
| AbbVie Inc. Dec 15, 2025 | Travel and Lodging OZURDEX · EYE CARE · travel to SAN ANTONIO, TX · in-kind | $130 |
| AbbVie Inc. Dec 15, 2025 | Travel and Lodging OZURDEX · EYE CARE · travel to SAN ANTONIO, TX · in-kind | $45.00 |
| AbbVie Inc. Dec 15, 2025 | Travel and Lodging OZURDEX · EYE CARE · travel to SAN ANTONIO, TX · in-kind | $33.98 |
| AbbVie Inc. Dec 15, 2025 | Travel and Lodging OZURDEX · EYE CARE · travel to SAN ANTONIO, TX · in-kind | $26.60 |
| Ani Pharmaceuticals, Inc. Nov 20, 2025 | Honoraria YUTIQ · Treatment of chronic non-infectious uveitis affecting the posterior segment of t | $1,575 |
| Genentech USA, Inc. Nov 15, 2025 | Consulting Fee | $6,100 |
| Genentech USA, Inc. Nov 15, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind | $366 |
| Genentech USA, Inc. Nov 15, 2025 | Travel and Lodging travel to San Francisco, CA | $240 |
| Genentech USA, Inc. Nov 15, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind | $231 |
| Ani Pharmaceuticals, Inc. Sep 17, 2025 | Honoraria PURIFIED CORTROPHIN GEL · Treatment of certain chronic autoimmune disorders including acute exacerbations | $1,850 |
| Bausch & Lomb Americas Inc. Sep 2, 2025 | Consulting Fee XIPERE · Ophthalmology | $2,000 |
| Bausch & Lomb Americas Inc. Sep 2, 2025 | Consulting Fee XIPERE · Ophthalmology | $1,000 |
| Bausch & Lomb Americas Inc. Jul 17, 2025 | Speaking at a medical education program XIPERE · Ophthalmology | $500 |
| AbbVie Inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) OZURDEX · EYE CARE | $1,125 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $18,621 in research payments for these studies, mostly to the institutions running them.
- A phase iii study to investigate RO7200220 in patients with uveitic macular edema
Genentech, Inc. - Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
Ani Pharmaceuticals, Inc. · Status unknown · NCT05322070
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.